Literature DB >> 10634516

Policy guidelines for the utilization of formalin-fixed, paraffin-embedded tissue sections: the UNC SPORE experience. University of North Carolina Specialized Program of Research Excellence.

L G Dressler1, J Geradts, M Burroughs, D Cowan, R C Millikan, B Newman.   

Abstract

Paraffin blocks represent a valuable resource that has allowed investigators to apply today's technology to address scientific questions in a shorter period of time and in more diverse populations than would have been possible with fresh or frozen tissue. However, in addition to being an exhaustible resource, there is concern regarding the appropriate use of these tissues, both with respect to medical or legal considerations and quality control and quality assurance practices. We describe policy guidelines to address these concerns, including: safeguards to address medical/legal and patient confidentiality issues, quality control and quality assurance for tissue sectioning, processing and storage, database management for sample tracking, and scientific review for utilization of specimens. These policies and procedures have been developed and implemented by the University of North Carolina (UNC) Specialized Program of Research Excellence (SPORE) in the Breast Cancer Immunohistochemistry (IHC) Core laboratory, in collaboration with our study pathologists, participants, and research investigators. It is our hope that the information and experience described here may stimulate discussion that can ultimately lead to a uniform policy for handling formalin-fixed paraffin-embedded tissues in research.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10634516     DOI: 10.1023/a:1006354627669

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  9 in total

1.  Breast tumor DNA methylation patterns associated with smoking in the Carolina Breast Cancer Study.

Authors:  Kathleen Conway; Sharon N Edmiston; Eloise Parrish; Christopher Bryant; Chiu-Kit Tse; Theresa Swift-Scanlan; Lauren E McCullough; Pei Fen Kuan
Journal:  Breast Cancer Res Treat       Date:  2017-03-08       Impact factor: 4.872

2.  Rational Manual and Automated Scoring Thresholds for the Immunohistochemical Detection of TP53 Missense Mutations in Human Breast Carcinomas.

Authors:  Nicholas J Taylor; Nana Nikolaishvili-Feinberg; Bentley R Midkiff; Kathleen Conway; Robert C Millikan; Joseph Geradts
Journal:  Appl Immunohistochem Mol Morphol       Date:  2016-07

3.  Epidemiology of basal-like breast cancer.

Authors:  Robert C Millikan; Beth Newman; Chiu-Kit Tse; Patricia G Moorman; Kathleen Conway; Lynn G Dressler; Lisa V Smith; Miriam H Labbok; Joseph Geradts; Jeannette T Bensen; Susan Jackson; Sarah Nyante; Chad Livasy; Lisa Carey; H Shelton Earp; Charles M Perou
Journal:  Breast Cancer Res Treat       Date:  2007-06-20       Impact factor: 4.872

4.  The estrogen receptor-alpha A908G (K303R) mutation occurs at a low frequency in invasive breast tumors: results from a population-based study.

Authors:  Kathleen Conway; Eloise Parrish; Sharon N Edmiston; Dawn Tolbert; Chiu-Kit Tse; Joseph Geradts; Chad A Livasy; Harsharan Singh; Beth Newman; Robert C Millikan
Journal:  Breast Cancer Res       Date:  2005-09-06       Impact factor: 6.466

5.  Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies.

Authors:  P de Graeff; J Hall; A P G Crijns; G H de Bock; J Paul; K A Oien; K A ten Hoor; S de Jong; H Hollema; J M S Bartlett; R Brown; A G J van der Zee
Journal:  Br J Cancer       Date:  2006-08-01       Impact factor: 7.640

6.  Use of formalin-fixed paraffin-embedded samples for gene expression studies in breast cancer patients.

Authors:  Valeria Musella; Maurizio Callari; Eleonora Di Buduo; Manuela Scuro; Matteo Dugo; Patrizia Miodini; Giampaolo Bianchini; Biagio Paolini; Luca Gianni; Maria Grazia Daidone; Vera Cappelletti
Journal:  PLoS One       Date:  2015-04-06       Impact factor: 3.240

7.  KDM3A is not associated with metastasis and prognosis of breast cancer.

Authors:  Juan Yao; Shutao Zheng; Baiyan Li; Xinxin Li; Wenya Liu
Journal:  Oncol Lett       Date:  2018-04-25       Impact factor: 2.967

8.  Risk factors for breast cancer characterized by the estrogen receptor alpha A908G (K303R) mutation.

Authors:  Kathleen Conway; Eloise Parrish; Sharon N Edmiston; Dawn Tolbert; Chiu-Kit Tse; Patricia Moorman; Beth Newman; Robert C Millikan
Journal:  Breast Cancer Res       Date:  2007       Impact factor: 6.466

9.  DNA methylation profiling in the Carolina Breast Cancer Study defines cancer subclasses differing in clinicopathologic characteristics and survival.

Authors:  Kathleen Conway; Sharon N Edmiston; Ryan May; Pei Fen Kuan; Haitao Chu; Christopher Bryant; Chiu-Kit Tse; Theresa Swift-Scanlan; Joseph Geradts; Melissa A Troester; Robert C Millikan
Journal:  Breast Cancer Res       Date:  2014-10-07       Impact factor: 6.466

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.